CRANBURY, N.J., March 3,
2022 /PRNewswire/ -- Palatin Technologies, Inc.
(NYSE American: PTN), a biopharmaceutical company developing
first-in-class medicines based on molecules that modulate the
activity of the melanocortin and natriuretic peptide receptor
systems, today announced that it will host a key opinion leader
(KOL) webinar on the unmet medical need in treating patients with
dry eye disease (DED) on Monday, March 7,
2022 at 10:30 am ET.
The webinar will feature a presentation from KOL Eric D.
Donnenfeld, M.D., from OCLI Vision, who will discuss the current
treatment landscape and unmet medical need in treating patients
with DED.
Palatin Technologies' Chief Medical Officer Michael Raizman, M.D. will also discuss their
Phase 3 trial for PL9643 in patients with dry eye disease. MELODY-1
clinical study is a multi-center, randomized, double–masked and
vehicle–controlled study evaluating the safety and efficacy of the
melanocortin agonist, PL9643 ophthalmic solution, compared to
vehicle in subjects with DED. The study is designed to enroll up to
400 patients at multiple U.S. sites, and top-line results are
currently expected second half calendar 2022.
The presentation will be followed by a question-and-answer
session with Dr. Donnenfeld, Dr. Raizman and Palatin senior
management. To register for the webinar and participate in the
webcast, please refer to Palatin's website at www.palatin.com or
click here.
Eric D. Donnenfeld, M.D. is an
internationally recognized expert and pioneer in refractive, cornea
and cataract surgery and one of the leading refractive and cataract
surgeons in the United States. Dr.
Donnenfeld graduated magna cum laude from Dartmouth College in 1977 and first in his class at
Dartmouth Medical School in 1980. He was Chief Resident at
Manhattan Eye, Ear and Throat Hospital and completed a Cornea and
Refractive Fellowship at Wills Eye Hospital. Dr. Donnenfeld is on
the Board of Overseers of Dartmouth Medical School and a Clinical
Professor of Ophthalmology at New York
University Medical Center.
Dr. Donnenfeld was the 2013-2014 President of the American
Society of Cataract and Refractive Surgery. Dr. Donnenfeld is the
Chief Medical Editor of EyeWorld, the official publication of the
American Society of Cataract and Refractive Surgery. He is on the
Executive Boards of ASCRS and ACOS and is a member of the
Refractive Committee of ASCRS and Cornea section of Ocular Surgery
News. Dr. Donnenfeld is a National Medical Director of TLC Laser
Eye Centers and Surgical Director of the Lions Eye Bank for Long
Island. He is a past president of the Ocular Microbiology and
Immunology Group. Locally, Dr. Donnenfeld has also served as a
board member of the Nassau Academy of Medicine, the American
College of Surgeons Long Island Chapter and the Nassau Surgical
Society and is a past president of the Nassau Surgical Society,
where he is the youngest person to ever receive their Lifetime
Achievement Award.
Michael B. Raizman, M.D. is a
cornea and cataract specialist at Ophthalmic Consultants of
Boston and the New England Eye
Center at Tufts Medical Center. He is Chief Medical Officer at
Palatin Technologies.
Dr. Raizman received his medical training at the University of Michigan and Harvard Medical School. He completed two
fellowships at the Massachusetts Eye & Ear Infirmary, followed
by three years of post-doctoral research at Harvard Medical School, funded by grants from the
National Institutes of Health. Dr. Raizman served on the full-time
faculty at Harvard Medical School from
1988-1991. Dr. Raizman is an Associate Professor of Ophthalmology
at Tufts University School of Medicine,
where he has directed the Corneal Fellowship Program and the Cornea
and Cataract Service since 1992. In that capacity, he has trained
over 50 Cornea Fellows. He is on the medical staff of the
Massachusetts General Hospital,
Massachusetts Eye and Ear, and Tufts Medical Center.
About Dry Eye Disease (DED)
Dry eye disease is a common inflammatory disease that, left
untreated, can become extremely painful and lead to permanent
damage to the cornea and vision. Dry eye disease affects the cornea
and conjunctiva of the eye resulting in irritation, redness, pain,
and blurred vision. It is estimated to affect over 20 million
people in the United States. The
disease is characterized by insufficient moisture and lubrication
in the anterior surface of the eye, leading to dryness,
inflammation, pain, discomfort, irritation, diminished quality of
life, and in severe cases, permanent vision impairment. Existing
therapy for dry eye disease is generally regarded as inadequate by
many physicians and patients, and often requires weeks or months to
demonstrate activity.
About Melanocortin Receptor Agonists and Inflammation
The melanocortin receptor ("MCr") system has effects on
inflammation, immune system responses, metabolism, food intake, and
sexual function. There are five melanocortin receptors, MC1r
through MC5r. Modulation of these receptors, through use of
receptor-specific agonists, which activate receptor function, or
receptor-specific antagonists, which block receptor function, can
have medically significant pharmacological effects.
Many tissues and immune cells located in the eye (and other
places, for example, the gut and kidney) express melanocortin
receptors, empowering our opportunity to directly activate natural
pathways to resolve disease inflammation.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class
medicines based on molecules that modulate the activity of the
melanocortin and natriuretic peptide receptor systems, with
targeted, receptor-specific product candidates for the treatment of
diseases with significant unmet medical need and commercial
potential. Palatin's strategy is to develop products and then form
marketing collaborations with industry leaders to maximize their
commercial potential. For additional information regarding Palatin,
please visit Palatin's website at www.Palatin.com.
Forward-looking Statements
Statements in this press release that are not historical facts,
including statements about future expectations of Palatin
Technologies, Inc., such as statements about market potential of
Vyleesi and other Palatin products in development, clinical trial
results, potential actions by regulatory agencies including the
FDA, regulatory plans, development programs, proposed indications
for product candidates, market potential for product candidates,
and potential adverse impacts due to the global COVID-19 pandemic
such as delays in regulatory review, manufacturing and supply chain
interruptions, adverse effects on healthcare systems and disruption
of the global economy, are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995. Palatin
intends that such forward-looking statements be subject to the safe
harbors created thereby. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that could
cause Palatin's actual results to be materially different from its
historical results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, Palatin's ability to
establish and maintain the capability for manufacturing, marketing
and distribution of Vyleesi, sales of Vyleesi in the United States and elsewhere in the world,
results of clinical trials, regulatory actions by the FDA and other
regulatory and the need for regulatory approvals, Palatin's ability
to fund development of its technology and establish and
successfully complete clinical trials, the length of time and cost
required to complete clinical trials and submit applications for
regulatory approvals, products developed by competing
pharmaceutical, biopharmaceutical and biotechnology companies,
commercial acceptance of Palatin's products, and other factors
discussed in Palatin's periodic filings with the Securities and
Exchange Commission. Palatin is not responsible for updating for
events that occur after the date of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-hosting-key-opinion-leader-webinar-on-dry-eye-disease-301494668.html
SOURCE Palatin Technologies, Inc.